Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We employ our advanced, specialised process to create targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q9UHX1

UPID:
PUF60_HUMAN

ALTERNATIVE NAMES:
60 kDa poly(U)-binding-splicing factor; FUSE-binding protein-interacting repressor; Ro-binding protein 1; Siah-binding protein 1

ALTERNATIVE UPACC:
Q9UHX1; A8K8K8; Q969E7; Q96D94; Q96H63; Q99628; Q9NZA0; Q9UJY7

BACKGROUND:
The Poly(U)-binding-splicing factor PUF60, known for its roles in RNA-binding, transcription regulation, and apoptosis, is crucial in cellular nuclear processes. It regulates MYC transcription, represses transcriptional activation by FUBP1, and modulates alternative splicing, highlighting its significance in gene expression and cell fate decisions.

THERAPEUTIC SIGNIFICANCE:
Given its involvement in Verheij syndrome, exploring Poly(U)-binding-splicing factor PUF60's function offers a promising avenue for therapeutic intervention. The protein's role in disease mechanisms provides a foundation for developing targeted treatments that could ameliorate or potentially cure conditions associated with its dysfunction.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.